Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-248 + Orelabrutinib vs Pirtobrutinib in r/r MCL
NCT07784101Phase 3Not yet recruiting
- Sponsor
- InnoCare Pharma
- Start
- Oct 2026
- Primary completion
- Oct 2032
- Countries
- 1
01
Overview
A Phase 3 trial of mesutoclax in mantle cell lymphoma (MCL), sponsored by InnoCare Pharma. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mesutoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07784101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784101.